A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors

Status:
Completed

Trial end date:
2018-07-26

Target enrollment:

Participant gender:

The purpose of this study is to confirm the safety and efficacy of sunitinib in subjects with unresectable pancreatic neuroendocrine tumors.

Phase 4

Pfizer

Sunitinib